Dealing with red, itchy eyelids? The culprit could be a common mite. This article is sponsored by XDEMVY. Dr. Watson is a ...

FDA approves XDEMVY (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis ... Prevalence of Demodex mites in eyelashes among people of Oaxaca, Mexico.

Tarsus Pharmaceuticals' lotilaner shows strong market performance for Demodex blepharitis, but cautious investment due to ...

which are small cylindrical structures formed by the mites, are a key diagnostic sign. They also noted that patients who do not respond to standard treatments should be evaluated for Demodex ...

Tarsus Pharmaceuticals, which has more than 100 of its 331 employees in Orange County, has plans to double its office space ...

This follows a successful 2024 for Tarsus, highlighted by the strong launch of XDEMVY, a treatment for Demodex ... are caused by an infestation of Demodex mites. This inflammatory condition ...

XDEMVY is indicated for the treatment of Demodex blepharitis. Most common side effects ... a well-characterized anti-parasitic agent that paralyzes and kills mites by selectively inhibiting ...

The science folks working for Tarsus had to go out and demonstrate that Demodex ... mites, plucking eyelashes and examining them under a microscope. I mean, yuck! Right? Before launching Xdemvy ...

Position Trading Today, the company sells one drug that could, potentially, treat 25 million people in the U.S. with Demodex ... mites, but don't really get to the root cause like our drug, Xdemvy ...

The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

Cory Jubinville, PhD, an analyst from LifeSci Capital, maintained the Buy rating on Tarsus Pharmaceuticals (TARS – Research Report). The ...